The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel

European Urology

Volumn 47, Issue 2, 2005, Pages 137-146

  Ebert, T ^a   Jockenhovel F ^b   Morales, A ^c   Shabsigh, R ^d  

^a Euromed Clinic   (Germany)

^b Evangelisches Krankenhaus Herne   (Germany)

^c QUEEN S UNIVERSITY   (Canada)

^d Center for Human Reproduction New York   (United States)

Author keywords

Erectile dysfunction; Hypogonadism; Osteoporosis; Prostate; PSA; SLOH; Testosterone gel

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PROSTATE SPECIFIC ANTIGEN; SILDENAFIL; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE HYDROXYLPROPYL BETA CYCLODEXTRIN; TESTOSTERONE UNDECANOATE; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; BLOOD CHEMISTRY; BONE DENSITY; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIGITAL RECTAL EXAMINATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ERECTILE DYSFUNCTION; HUMAN; HYPOGONADISM; LIVER TOXICITY; MOOD DISORDER; NONHUMAN; ONSET AGE; PATIENT MONITORING; POLYCYTHEMIA; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SEXUAL DYSFUNCTION; SYMPTOMATIC LATE ONSET HYPOGONADISM; TESTOSTERONE BLOOD LEVEL;

ADMINISTRATION, CUTANEOUS; GONADAL HORMONES; HUMANS; HYPOGONADISM; IMPOTENCE; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 12344296426     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.09.015     Document Type: Review

References (70)

1. D.A. Gruenewald, and A.M. Matsumoto Testosterone supplementation therapy for older men: potential benefits and risks J Am Geriatr Soc 51 2003 101 115 discussion 115
2. Morales A. Andropause (or symptomatic late-onset hypogonadism): Facts, myths and controversies. Aging Male 2004; in press.
3. L.A.J. Heinemann, F. Saad, T. Thiele, and S. Wood-Dauphinee The Aging Males' Symptoms rating scale: cultural and linguistic validation into English Aging Male 4 2001 14 22
4. J.E. Morley, P. Patrick, and H.M. Perry 3rd Evaluation of assays available to measure free testosterone Metabolism 51 2002 554 559
5. Jockenhoevel F. Male Hypogonadism. Bremen: UNI-MED Verlag AG; 2004.
6. F. Jockenhovel Testosterone supplementation: what and how to give Aging Male 6 2003 200 206
7. A. Morales, and B. Lunenfeld Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male Aging Male 5 2002 74 86
8. A. Hameed, T. Brothwood, and P. Bouloux Delivery of testosterone replacement therapy Curr Opin Investig Drugs 4 2003 1213 1219
9. M.A. Mackey, A.J. Conway, and D.J. Handelsman Tolerability of intramuscular injections of testosterone ester in oil vehicle Hum Reprod 10 1995 862 865
10. E. Nieschlag, H.J. Cuppers, W. Wiegelmann, and E.J. Wickings Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men Horm Res 7 1976 138 145
11. T. Schurmeyer, and E. Nieschlag Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men Int J Androl 7 1984 181 187
12. S. Eckardstein, and E. Nieschlag Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: A phase II study J Androl 23 2002 419 425
13. F.M. Kohn, and W.B. Schill A new oral testosterone undecanoate formulation World J Urol 21 2003 311 315
14. N.C. Park, B.Q. Yan, J.M. Chung, and K.M. Lee Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency Aging Male 6 2003 86 93
15. A. Morales, B. Johnston, J.P. Heaton, and M. Lundie Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes J Urol 157 1997 849 854
16. A.S. Dobs, A.M. Matsumoto, C. Wang, and M.S. Kipnes Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men Curr Med Res Opin 20 2004 729 738
17. M. Korbonits, M. Slawik, D. Cullen, R.J. Ross, G. Stalla, and H. Schneider A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males J Clin Endocrinol Metab 89 2004 2039 2043
18. R.J. Ross, A. Jabbar, T.H. Jones, B. Roberts, K. Dunkley, and J. Hall Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men Eur J Endocrinol 150 2004 57 63
19. C.A. Stuenkel, R.E. Dudley, and S.S. Yen Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men J Clin Endocrinol Metab 72 1991 1054 1059
20. J.C. Findlay, V. Place, and P.J. Snyder Treatment of primary hypogonadism in men by the transdermal administration of testosterone J Clin Endocrinol Metab 68 1989 369 373
21. M. Bals-Pratsch, U.A. Knuth, Y.D. Yoon, and E. Nieschlag Transdermal testosterone substitution therapy for male hypogonadism Lancet 2 1986 943 946
22. S.G. Korenman, S. Viosca, D. Garza, M. Guralnik, V. Place, and P. Campbell Androgen therapy of hypogonadal men with transscrotal testosterone systems Am J Med 83 1987 471 478
23. S.R. Ahmed, A.E. Boucher, A. Manni, R.J. Santen, M. Bartholomew, and L.M. Demers Transdermal testosterone therapy in the treatment of male hypogonadism J Clin Endocrinol Metab 66 1988 546 551
24. P.J. Snyder, H. Peachey, J.A. Berlin, P. Hannoush, G. Haddad, and A. Dlewati Effects of testosterone replacement in hypogonadal men J Clin Endocrinol Metab 85 2000 2670 2677
25. A.S. Dobs, A.W. Meikle, S. Arver, S.W. Sanders, K.E. Caramelli, and N.A. Mazer Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men J Clin Endocrinol Metab 84 1999 3469 3478
26. A.W. Meikle, S. Arver, A.S. Dobs, S.W. Sanders, L. Rajaram, and N.A. Mazer Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site - a clinical research center study J Clin Endocrinol Metab 81 1996 1832 1840
27. S. Parker, and M. Armitage Experience with transdermal testosterone replacement therapy for hypogonadal men Clin Endocrinol (Oxf) 50 1999 57 62
28. R.S. Swerdloff, C. Wang, G. Cunningham, A. Dobs, A. Iranmanesh, and A.M. Matsumoto Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men J Clin Endocrinol Metab 85 2000 4500 4510
29. C. Wang, R.S. Swerdloff, A. Iranmanesh, A. Dobs, P.J. Snyder, and G. Cunningham Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group J Clin Endocrinol Metab 85 2000 2839 2853
30. C. Wang, N. Berman, J.A. Longstreth, B. Chuapoco, L. Hull, and B. Steiner Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study J Clin Endocrinol Metab 85 2000 964 969
31. T.A. McNicholas, J.D. Dean, H. Mulder, C. Carnegie, and N.A. Jones A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function BJU Int 91 2003 69 74
32. T. Marbury, E. Hamill, R. Bachand, T. Sebree, and T. Smith Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel Biopharm Drug Dispos 24 2003 115 120
33. C. Rolf, U. Knie, G. Lemmnitz, and E. Nieschlag Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation Clin Endocrinol (Oxf) 56 2002 637 641
34. C. Wang, R.S. Swerdloff, A. Iranmanesh, A. Dobs, P.J. Snyder, and G. Cunningham Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men Clin Endocrinol (Oxf) 54 2001 739 750
35. R.S. Swerdloff, and C. Wang Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel Aging Male 6 2003 207 211
36. H.G. Pope Jr., G.H. Cohane, G. Kanayama, A.J. Siegel, and J.I. Hudson Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial Am J Psychiatry 160 2003 105 111
37. F.J. Hayes Testosterone - fountain of youth or drug of abuse? J Clin Endocrinol Metab 85 2000 3020 3023
38. A. Morales, and J.P. Heaton Hormonal erectile dysfunction. Evaluation and management Urol Clin North Am 28 2001 279 288
39. J. Buvat, and A. Lemaire Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy J Urol 158 1997 1764 1767
40. R. Shabsigh Hypogonadism and erectile dysfunction: the role for testosterone therapy Int J Impot Res 15 Suppl 4 2003 S9 S13
41. R. Shabsigh The effects of testosterone on the cavernous tissue and erectile function World J Urol 15 1997 21 26
42. R. Shabsigh, J.F. Raymond, C.A. Olsson, K. O'Toole, and R. Buttyan Androgen induction of DNA synthesis in the rat penis Urology 52 1998 723 728
43. S.Y. Kalinchenko, G.I. Kozlov, N.P. Gontcharov, and G.V. Katsiya Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone Aging Male 6 2003 94 99
44. A. Aversa, A.M. Isidori, G. Spera, A. Lenzi, and A. Fabbri Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction Clin Endocrinol (Oxf) 58 2003 632 638
45. R. Shabsigh, J.M. Kaufman, C. Steidle, and H. Padma-Nathan Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone J Urol 172 2004 658 663
46. S. Arver, A.S. Dobs, A.W. Meikle, R.P. Allen, S.W. Sanders, and N.A. Mazer Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system J Urol 155 1996 1604 1608
47. A. Morales, J. Buvat, L.J. Gooren, A.T. Guay, J.-M. Kaufman, and H.M. Tan Endocrine aspects of sexual dysfunction in men J Sexual Medicine 1 2004 69 81
48. T.F. Lue, F. Giuliano, F. Montorsi, R.C. Rosen, K.-E. Andersson, and S. Althof Summary of the recommendations on sexual dysfunctions in men J Sexual Medicine 1 2004 6 23
49. R.S. Swerdloff, and C. Wang Androgens and aging in men Exp Gerontol 28 1993 435 446
50. F.H. Schroder EORTC Genitourinary Group: prostate cancer studies Prog Clin Biol Res 357 1990 73 81
51. J.E. Fowler Jr., and W.F. Whitmore Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone J Urol 126 1981 372 375
52. P.L. Zhang, S. Rosen, R. Veeramachaneni, J. Kao, W.C. DeWolf, and G. Bubley Association between prostate cancer and serum testosterone levels Prostate 53 2002 179 182
53. E.L. Rhoden, and A. Morgentaler Risks of testosterone-replacement therapy and recommendations for monitoring N Engl J Med 350 2004 482 492
54. E. Flores, E. Bratoeff, M. Cabeza, E. Ramirez, A. Quiroz, and I. Heuze Steroid 5alpha-reductase inhibitors Mini Rev Med Chem 3 2003 225 237
55. E.G. Occhiato, A. Guarna, G. Danza, and M. Serio Selective non-steroidal inhibitors of 5 alpha-reductase type 1 J Steroid Biochem Mol Biol 88 2004 1 16
56. I.M. Thompson, P.J. Goodman, C.M. Tangen, M.S. Lucia, G.J. Miller, and L.G. Ford The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224
57. S. Slater, and R.T. Oliver Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy Drugs Aging 17 2000 431 439
58. R.E. Gerstenbluth, P.N. Maniam, E.W. Corty, and A.D. Seftel Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement J Androl 23 2002 922 926
59. E.L. Rhoden, and A. Morgentaler Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia J Urol 170 2003 2348 2351
60. H.M. Behre, J. Bohmeyer, and E. Nieschlag Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls Clin Endocrinol (Oxf) 40 1994 341 349
61. A.W. Meikle, S. Arver, A.S. Dobs, J. Adolfsson, S.W. Sanders, and R.G. Middleton Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system Urology 49 1997 191 196
62. A.M. Kenny, K.M. Prestwood, C.A. Gruman, K.M. Marcello, and L.G. Raisz Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels J Gerontol A Biol Sci Med Sci 56 2001 M266 M272
63. J.M. Zmuda, J.A. Cauley, A. Kriska, N.W. Glynn, J.P. Gutai, and L.H. Kuller Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants Am J Epidemiol 146 1997 609 617
64. G.B. Phillips, B.H. Pinkernell, and T.Y. Jing The association of hypotestosteronemia with coronary artery disease in men Arterioscler Thromb 14 1994 701 706
65. B.S. Uyanik, Z. Ari, B. Gumus, M.R. Yigitoglu, and T. Arslan Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study Jpn Heart J 38 1997 73 82
66. D. Crook Androgens and the risk of cardiovascular disease Aging Male 3 2000 190 195
67. L.J.G. Gooren Visceral obesity, androgens and the risk of cardiovascular disease and diabetes mellitus Aging Male 4 2001 30 38
68. F. Jockenhovel, C. Bullmann, M. Schubert, E. Vogel, W. Reinhardt, and D. Reinwein Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men Metabolism 48 1999 590 596
69. F. Jockenhovel, E. Vogel, W. Reinhardt, and D. Reinwein Effects of various modes of androgen substitution therapy on erythropoiesis Eur J Med Res 2 1997 293 298
70. C.T. Liverman D.G. Blazer Testosterone and aging. Committee on assessing the need for clinical trials of testosterone replacement therapy 2004 The National Academies Press Institute of Medicine of the National Academies. Washington (DC)